Stoke Therapeutics (NASDAQ:STOK) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Stoke Therapeutics (NASDAQ:STOK) announced its earnings results on Tuesday. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05, Zacks reports. The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Stoke Therapeutics Trading Up 0.2 %

STOK stock opened at $13.27 on Friday. Stoke Therapeutics has a 52-week low of $3.77 and a 52-week high of $17.58. The business has a 50-day simple moving average of $13.24 and a two-hundred day simple moving average of $13.70.

Insider Transactions at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares in the company, valued at $125,131,843.05. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 11.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Wedbush reissued an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.